1. Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer
   Xóchitl Zambrano-Estrada et al, 2018, BMC Vet Res CrossRef
2. Overexpression of HER-2 via immunohistochemistry in canine urinary bladder transitional cell carcinoma - A marker of malignancy and possible therapeutic target.
   F Millanta et al, 2018, Vet Comp Oncol CrossRef
3. Cancer Immunotherapies
   Philip J. Bergman, 2019, Veterinary Clinics of North America: Small Animal Practice CrossRef
4. AllergoOncology - the impact of allergy in oncology: EAACI position paper
   E. Jensen-Jarolim et al, 2017, Allergy CrossRef
5. ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)
   Dane A. Hayes et al, 2017, PLoS ONE CrossRef
6. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells
   Yoseop Kim et al, 2019, BMC Vet Res CrossRef
7. Translational oncotargets for immunotherapy: from pet dogs to humans
   Lisa A. Mestrinho et al, 2021, Advanced Drug Delivery Reviews CrossRef
8. Harnessing the Anti-Tumor Mediators in Mast Cells as a New Strategy for Adoptive Cell Transfer for Cancer
   Mohammad Fereydouni et al, 2022, Front. Oncol. CrossRef
9. Defucosylated Mouse-Dog Chimeric Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody (H77Bf) Exerts Antitumor Activities in Mouse Xenograft Models of Canine Osteosarcoma
   Ren Nanamiya et al, 2022, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy CrossRef
10. Canine mammary carcinoma: current therapeutic targets and future perspectives – a review
    Muhammad Luqman Nordin et al, 2023 CrossRef
11. Cancer Immunotherapy
    Philip J. Bergman, 2023, Veterinary Clinics of North America: Small Animal Practice CrossRef
12. Targeting CD200 in Breast Cancer: Opportunities and Challenges in Immunotherapeutic Strategies
    Sihyang Baek et al, 2024, IJMS CrossRef